Skyrizi Complete Savings Card

Funded
About
The Skyrizi Complete Savings Card program offers significant financial benefits for patients needing the medication Skyrizi. With coverage for eligible commercially insured patients, the Skyrizi Complete Savings Card allows patients to potentially pay as little as $0 per dose, ensuring access to essential treatment while minimizing out-of-pocket expenses.
Insurance requirements: Commercially insured
Enrollment Forms
Enrollment Form
Program Requirements
Valid only for residents in the US and Puerto Rico
Enrollment Required: Yes
Coverage Required: No
Needs Based: No
Activation Required: No
Program Details
Eligible commercially insured patients may pay as little as $0 per dose
Maximum benefit of $14,000 per calendar year
Maximum saving limit applies; patient outofpocket expense may vary on a monthly, quarterly, and/or annual basis depending on each individual patient’s plan of insurance and other prescription drug costs
Benefit covers all approved indications for Skyrizi; for psoriatic arthritis patients, the benefit covers SKYRIZI plus one of the following medications: methotrexate, leflunomide, or hydroxychloroquine
For Crohn’s disease patients, this benefit covers SKYRIZI alone or for SKYRIZI with product associated infusion (maximum savings limit of $1,000 per year applies) and eligible liver enzyme and bilirubin lab monitoring costs (maximum savings limit of $1,000 per year applies) where the full cost is not covered by a patient’s insurance
For Crohn's disease ONLY: Patient or healthcare provider is required to submit an Explanation of Benefits (EOB) following each infusion and/or laboratory test to the CoPay Program
Crohn's patients: Online rebate submission: https://www.skyrizi.com/skyrizicomplete/crohns/labrebates
Skyrizi Infusion Reimbursement Options and Fax form for Crohn's patients: https://www.skyrizihcp.com/content/dam/skyrizihcpivy/docs/reimbursementoptionsform.pdf
Reimbursement support (Crohn's patients): 8772667538 or 8004710186 option 5
If AbbVie determines that you are subject to a copay maximizer program, (even if the patient is unaware of the fact), except where prohibited by applicable state law, AbbVie may discontinue the availability of copay support at an amount not to exceed $4,000
Other Programs

Assistance Fund: Crohn's Disease: Waitlist

Commercially Insured
Medicare / Medicaid
Underinsured

Assistance Fund: Psoriasis

Commercially Insured
Medicare / Medicaid
Other Tools for Skyrizi